select a format

Single User License
USD 2000 INR 130240
Site License
USD 4000 INR 260480
Corporate User License
USD 6000 INR 390720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Metastatic Uveal Melanoma-Pipeline Review, H2 2016

Metastatic Uveal Melanoma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8909IDB
  • |
  • Pages: 56
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Metastatic Uveal Melanoma-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma-Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Metastatic Uveal Melanoma Overview 6

Therapeutics Development 7

Pipeline Products for Metastatic Uveal Melanoma-Overview 7

Pipeline Products for Metastatic Uveal Melanoma-Comparative Analysis 8

Metastatic Uveal Melanoma-Therapeutics under Development by Companies 9

Metastatic Uveal Melanoma-Therapeutics under Investigation by Universities/Institutes 10

Metastatic Uveal Melanoma-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Metastatic Uveal Melanoma-Products under Development by Companies 13

Metastatic Uveal Melanoma-Products under Investigation by Universities/Institutes 14

Metastatic Uveal Melanoma-Companies Involved in Therapeutics Development 15

Bellicum Pharmaceuticals Inc 15

Celldex Therapeutics Inc 16

Eli Lilly and Company 17

Novartis AG 18

Spectrum Pharmaceuticals Inc 19

Metastatic Uveal Melanoma-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

alpelisib-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BPX-701-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

emibetuzumab-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

glembatumumab vedotin-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

KCN-1-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

LXS-196-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

merestinib-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

sotrastaurin acetate-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

vincristine sulfate-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Metastatic Uveal Melanoma-Dormant Projects 51

Metastatic Uveal Melanoma-Discontinued Products 52

Metastatic Uveal Melanoma-Product Development Milestones 53

Featured News & Press Releases 53

Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 53

Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Figures

Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7

Number of Products under Development for Metastatic Uveal Melanoma-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

List of Tables

Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7

Number of Products under Development for Metastatic Uveal Melanoma-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Metastatic Uveal Melanoma-Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 15

Metastatic Uveal Melanoma-Pipeline by Celldex Therapeutics Inc, H2 2016 16

Metastatic Uveal Melanoma-Pipeline by Eli Lilly and Company, H2 2016 17

Metastatic Uveal Melanoma-Pipeline by Novartis AG, H2 2016 18

Metastatic Uveal Melanoma-Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Metastatic Uveal Melanoma-Dormant Projects, H2 2016 51

Metastatic Uveal Melanoma-Discontinued Products, H2 2016 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bellicum Pharmaceuticals Inc, Celldex Therapeutics Inc, Eli Lilly and Company, Novartis AG, Spectrum Pharmaceuticals Inc

Metastatic Uveal Melanoma Therapeutic Products under Development, Key Players in Metastatic Uveal Melanoma Therapeutics, Metastatic Uveal Melanoma Pipeline Overview, Metastatic Uveal Melanoma Pipeline, Metastatic Uveal Melanoma Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com